Trump Administration Ready to Tackle Drug Prices
President Donald Trump is expected to sign an executive order that addresses rising drug prices. According to The Hill, the order is expected to be an interim step and not request any drastic changes. The Trump administration is considering directing agencies to pursue value-based purchasing contracts for drugs. Executive orders aren’t laws, but they are used to direct agencies in how to pursue regulatory actions.
Rival to EpiPen Approved
The FDA has approved an emergency epinephrine syringe that will be a lower-cost rival to EpiPen. The pre-filled epinephrine syringes are for emergency use to treat severe allergic reactions; however, at this time the cost of Symjepi has not been announced, reported Reuters. There are other competitors to the EpiPen available, but for years, Mylan has owned more than 90% of the market. Mylan’s generic of its own injector still costs about $300.
No Consensus on Senate Health Bill Deadline
While there has been talk of voting on a Senate healthcare bill by the end of June, there is no consensus regarding whether or not Republicans will meet that deadline. On Thursday, The Washington Post reported that the goal is to bring the bill to a vote on the Senate floor by the end of June. However, a day later, Politico claimed the Senate is likely to miss that deadline. The Senate has just 2 weeks until the Fourth of July recess, yet there are reports of remaining divisions on how to roll back Medicaid expansion and how much to cut from the program.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More